Neena Brizmohun
Executive Editor
Neena has been covering regulatory, business and market access developments that impact pharmaceutical and medical device companies since 1997. She explores the challenges and opportunities that developments worldwide introduce for industry and regulators. Her areas of expertise include regulatory schemes for getting products to market faster. Neena's other specialist areas include new medicines coming to market in the EU, pricing and reimbursement, clinical trials, real-world evidence, post-marketing safety monitoring, transparency policies relating to the publication of trial data, and global harmonization initiatives for pharma and medtech.
Latest From Neena Brizmohun
EU CHMP Opinions And MAA Updates
This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.
Additional Analyses Help Idorsia Secure English Funding For Chronic Insomnia Drug Quviviq
Quviviq is to become the first dual orexin receptor antagonist available on the National Health Service. Just over 20,000 people in England could receive treatment with the drug in its first year, says the health technology assessment institute, NICE.
Lack of Adequate Study Plan Prompts EMA Review Of Cardiovascular Risk With Mysimba
The European Medicines Agency is to recommend whether the marketing authorization for Currax’s weight management drug should be maintained, varied, suspended or revoked.
Potential Blockbuster Lebrikizumab Among Latest Drugs Up For Decision On EU Approval
The European Medicines Agency is set to decide whether to back EU marketing approval for eight new drugs.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add four new products, including Abrysvo, Pfizer's RSV vaccine for use in older adults and for the immunization of pregnant women to help protect their infants immediately from birth through six months of age.
Quotable: Top Experts On Policy Hot Topics
The Pink Sheet highlights recent comments and insights from pharma officials and executives on key issues we are covering.